Dr. Todd Hobbs discusses diabetes and obesity related projects at Novo Nordisk, including the results of the DEVOTE trial: the cardiovascular outcomes trial for degludec, basal insulin.
Read More »Todd Hobbs Full Interview
n this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about data from various important trials as well as the importance of their unique product degludec.
Read More »Todd Hobbs Part 1, Background and Introduction
In part 1 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about his work at Novo Nordisk not only as chief medical officer but also as a person with type 1.
Read More »Todd Hobbs Part 2, Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine
In part 2 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about DEVOTE data and how degludec works.
Read More »Todd Hobbs Part 3, Dual 7 Trial-Xultophy
In part 3 of this Exclusive Interview, Dr. Todd Hobbs explains the DUAL-7 data in a converstion with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.
Read More »Todd Hobbs Part 4, GLP-1 Drug Trials
In part 4 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the GLP-1 cardiovascular trials and the significance of the LEADER study.
Read More »Todd Hobbs Part 5, The Future of Novo Nordisk
In part 5, the conclusion, of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about what's in the pipeline for Novo Nordisk and smart insulin.
Read More »Current Interview: Henry Anhalt and Howard Steinberg
Henry Anhalt, DO (left), is a pediatric endocrinologist in Hackensack, NJ who was most recently the Chief Medical Officer of the T1D Exchange, a nonprofit organization that has created a new paradigm fostering collaboration among patients, physicians, researchers and industry to speed discovery of better therapies for type 1 diabetes. Howard Steinberg went from brand management at the Pepsi Cola Co to applying his personal understanding of diabetes - he has lived with type 1 diabetes since age 10 - to create the multimedia DTC platform dLife, which he founded in 2005.
Read More »Henry Anhalt and Howard Steinberg Full Interview
In this Exclusive Interview, Henry Anhalt and Howard Steinberg talk with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the work of Insulin for Life USA, an affiliate of the global organization that works to bring much-needed insulin to those in need in developing countries.
Read More »Henry Anhalt and Howard Steinberg Transcript
Steve Freed: This is Steve Freed with Diabetes in Control and we’re here in San Diego for the American Diabetes Association 77th Scientific Sessions. We have some really great interviews with some of the top endo’s all across the globe. We have two special guests here, Henry Anhalt and Howard …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.